Literature DB >> 7444223

Predicted gas exchange on the summit of Mt. Everest.

J B West, P D Wagner.   

Abstract

The ascent of Mt. Everest (altitude 8848 m) by two climbers in May 1978 without supplementary oxygen has prompted us to make a theoretical analysis of gas exchange under these conditions of extreme hypoxia. On the basis of previous measurements made up to an altitude of 7440 m and other data, we have calculated a barometric pressure on the summit of 250 Torr, alveolar PCO2 of 10 Torr, and Hb concentration of 20.5 g/100 ml. Values for cardiac output, pulmonary capillary blood volume, and diffusing capacity were based on measurements made at 5800 m. A striking result of calculations of oxygenation along the pulmonary capillary is that, even at rest, there is an alveolar-end capillary PO2 of about 6 Torr caused by diffusion limitation, and this widens rapidly on mild exercise. Arterial and mixed venous PO2 fall precipitously as the VO2 is raised further. If we assume that the PO2 in mixed venous blood cannot fall below 15 Torr, a maximal VO2 of less than 700 ml/min is predicted. Arterial O2 saturation and, to a smaller extent, the mixed venous PO2 can be increased by shifting the O2 dissociation curve to the left. This can be accomplished by fully compensating for the respiratory alkalosis at a lower altitude, and then climbing rapidly to the summit. Maximal VO2 is extremely sensitive to barometric pressure, and to a lesser extent to lung diffusing capacity. The results are in general agreement with extrapolations from measurements of maximal VO2 at altitudes up to 7440 m.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7444223     DOI: 10.1016/0034-5687(80)90100-0

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  15 in total

Review 1.  The last "oxygenless" ascent of Mt. Everest.

Authors:  D M Bailey
Journal:  Br J Sports Med       Date:  2001-10       Impact factor: 13.800

Review 2.  Limiting factors to oxygen transport on Mount Everest 30 years after: a critique of Paolo Cerretelli's contribution to the study of altitude physiology.

Authors:  Guido Ferretti
Journal:  Eur J Appl Physiol       Date:  2003-10-03       Impact factor: 3.078

3.  Operation Everest II.

Authors:  Peter D Wagner
Journal:  High Alt Med Biol       Date:  2010       Impact factor: 1.981

4.  Effect of blood haemoglobin concentration on V(O2,max) and cardiovascular function in lowlanders acclimatised to 5260 m.

Authors:  J A L Calbet; G Rådegran; R Boushel; H Søndergaard; B Saltin; P D Wagner
Journal:  J Physiol       Date:  2002-12-01       Impact factor: 5.182

Review 5.  Hemoglobin-oxygen affinity in high-altitude vertebrates: is there evidence for an adaptive trend?

Authors:  Jay F Storz
Journal:  J Exp Biol       Date:  2016-10-15       Impact factor: 3.312

6.  Decreased critical mixed venous oxygen tension and critical oxygen transport during induced hypothermia in pigs.

Authors:  D C Willford; E P Hill; F C White; W Y Moores
Journal:  J Clin Monit       Date:  1986-07

Review 7.  [Air travel and respiratory diseases].

Authors:  Francisco García Río; Luis Borderías Clau; Ciro Casanova Macario; Bartolomé R Celli; Joan Escarrabill Sanglás; Nicolás González Mangado; Josep Roca Torrent; Fernando Uresandi Romero
Journal:  Arch Bronconeumol       Date:  2007-02       Impact factor: 4.872

8.  Increased blood-oxygen binding affinity in Tibetan and Han Chinese residents at 4200 m.

Authors:  T S Simonson; G Wei; H E Wagner; T Wuren; A Bui; J M Fine; G Qin; F G Beltrami; M Yan; P D Wagner; Ri Li Ge
Journal:  Exp Physiol       Date:  2014-08-28       Impact factor: 2.969

9.  Theoretical analysis of oxygen transport during hypothermia.

Authors:  D C Willford; E P Hill; W Y Moores
Journal:  J Clin Monit       Date:  1986-01

10.  Death Zone Weather Extremes Mountaineers Have Experienced in Successful Ascents.

Authors:  Robert K Szymczak; Michał Marosz; Tomasz Grzywacz; Magdalena Sawicka; Marta Naczyk
Journal:  Front Physiol       Date:  2021-07-05       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.